Clinical trials: sponsored by Canadian Cancer Trials Group
Breast Cancer
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258375
- Testing
- custirsen sodium, docetaxel
- Where
- 5 sites in Canada
- Volunteers
- 15 people
- Sponsor
- NCIC Clinical Trials Group
Gynecologic Cancer
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.
- Trial name
- NCT02459301
- Testing
- IPH2201
- Where
- 7 sites in Canada
- Volunteers
- 59 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.
- Trial name
- NCT01708993
- Testing
- Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin
- Where
- 12 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258388
- Testing
- custirsen sodium, docetaxel, prednisone
- Where
- 13 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- NCIC Clinical Trials Group
Endometrial Cancer
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00770185
- Testing
- ridaforolimus, gene expression analysis, immunohistochemistry staining method
- Where
- 11 sites in Canada
- Volunteers
- 35 people
- Sponsor
- NCIC Clinical Trials Group
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out if giving Reolysin in combination with docetaxel and prednisone can offer better results than standard therapy with docetaxel and prednisone.
- Trial name
- NCT01619813
- Testing
- Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone
- Where
- 11 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00688246
- Testing
- biologic sample preservation procedure, dual x-ray absorptometry
- Where
- 18 sites in United States, Canada
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00305812
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- 14 sites in Canada
- Volunteers
- 51 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group
Malignant Pleural Mesothelioma
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
- Trial name
- NCT01486368
- Testing
- PF-03446962
- Where
- 7 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Lymphoma
Bortezomib in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have previously…
- Trial name
- NCT00030875
- Testing
- bortezomib
- Where
- 10 sites in Canada
- Volunteers
- 30 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Head and Neck Squamous Cell Carcinoma
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
The usual approach for patients who are not in a study is treatment with pembrolizumab, a type of immunotherapy drug. Immunotherapy works by allowing the immune system to detect your cancer and reactivate the immune response.
- Trial name
- PROMOTE-HN (NCT05743777)
- Testing
- Pembrolizumab, MET-4
- Sponsor
- Canadian Cancer Trials Group
Gastro-Oesophageal Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
- Trial name
- INTEGRATEIIa (NCT02773524)
- Testing
- Regorafenib
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
This is a multicentric randomized phase III trial comparing adjuvant chemotherapy with gemcitabine versus 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFolfirinox) in patients with resected pancreatic adenocarcinoma.
- Trial name
- NCT01526135
- Testing
- mFolfirinox, Gemcitabine
- Where
- 52 sites in Canada, France
- Volunteers
- 493 people
- Sponsor
- UNICANCER
Melanoma, Brain Metastases
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown to increase tumour shrinkage in animals…
- Trial name
- NCT02974803
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Neuroblastoma
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.
- Trial name
- NCT01916187
- Testing
- Imetelstat
- Where
- Canada
- Sponsor
- NCIC Clinical Trials Group
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is…
- Conditions
- Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT00005970
- Testing
- Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 157 sites in United States, Canada and 2 more
- Volunteers
- 3,436 people
- Sponsor
- National Cancer Institute (NCI)